Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Last year’s funding cuts at the National Institutes of Health (NIH) disproportionately impacted women and early-career ...

Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the world’s largest production ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, ...

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce ...

Stryker continues to dig itself out of the hole left by the global cyberattack it suffered nearly two weeks ago, saying its ...

In this episode of The Top Line, Olive McCormick joins host Chris Hayden to examine one of the most overlooked risks in ...

Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...